Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

BioLineRx Ltd.

Hold a pre-NDA meeting with the FDA for stem-cell mobilization indication

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
23 Feb 2021
Due
31 Dec 2021
Delivered
December 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“including a pre-NDA meeting with the FDA planned for the second half of 2021.”
  • SourceBioLineRx Ltd. Form 6-K press release, 2021-02-23
  • FilingSEC filing index
  • Deadline as statedfor the second half of 2021
  • Deadline used31 Dec 2021, the last day of the stated period
  • TypeRegulatory
  • Permanent referenceKI-C-2021-BLRX-024232
    Cite as https://keptindex.org/c/KI-C-2021-BLRX-024232/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company held its pre-NDA meeting with the FDA in December 2021, within the second-half 2021 window, and the FDA agreed the data package was sufficient for an NDA.

  • A
    BioLineRx Ltd. 6-K filed 2022-01-18 Regulatory filing · published 18 Jan 2022 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients” ✓ confirmed on the page
  • A
    BioLineRx Ltd. 6-K filed 2022-03-16 Regulatory filing · published 16 Mar 2022 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “Following our very productive pre-NDA meeting with FDA that we completed in December, we are diligently working to submit the NDA” ✓ confirmed on the page
  • A
    BioLineRx Ltd. 20-F filed 2022-03-16 Regulatory filing · published 16 Mar 2022 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “In December 2021, we held a pre-NDA meeting with the FDA. The purpose of the meeting was to obtain agreement from the FDA on the content of the proposed NDA” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Regulatory other
Indicative materiality
Medium rules
Action
Hold
Deliverable
Pre-NDA meeting with FDA for SCM
Where
United States
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
Medium
Depends on
Government

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you BioLineRx Ltd.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-BLRX-024232 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.